drugset / Trial / NCT03487107
Phase 3 Study of Yimitasvir Phosphate Capsules
NaSingle-groupOpen-labelTreatment
Summary
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.
Timeline
- Start
- 2018-04-17
- Primary completion
- 2019-03-28
- Completion
- 2019-06-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOF | Unknown | 400 mg | Oral |
| Subject | Yimitasvir | Small molecule | 100 mg | Oral |